CDK4 and hepatocellular carcinoma: Therefore, we believe that targeting ML-323 or USP1 can increase the sensitivity of HCC cells to sorafenib treatment by inhibiting the expression of cyclin E1, cyclin D1, CDK2, and CDK4.